Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Multiple Myeloma”

1,673 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,673 results

Testing effectiveness (Phase 2)Study completedNCT00002907
What this trial is testing

Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Barbara Ann Karmanos Cancer Institute
Early research (Phase 1)UnknownNCT03015922
What this trial is testing

Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Leeds 4
Not applicableStudy completedNCT00521430
What this trial is testing

Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+3 more
Asan Medical Center 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT06303167
What this trial is testing

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 19
Not applicableStudy completedNCT01904175
What this trial is testing

Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant

Who this might be right for
Hodgkin's DiseaseNon Hodgkin's LymphomaMyeloma+2 more
Duke University 48
Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Not applicableStudy completedNCT02976493
What this trial is testing

Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 500
Testing effectiveness (Phase 2)WithdrawnNCT01652014
What this trial is testing

Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Lymphoblastic Leukemia in Remission+51 more
University of Medicine and Dentistry of New Jersey
Testing effectiveness (Phase 2)Study completedNCT00602706
What this trial is testing

Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Mayo Clinic 76
Early research (Phase 1)Study completedNCT05270928
What this trial is testing

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#

Who this might be right for
Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital of Soochow University 6
Early research (Phase 1)Ended earlyNCT04045028
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Multiple MyelomaNon-Hodgkin LymphomaB-Cell Lymphoma
Genentech, Inc. 41
Testing effectiveness (Phase 2)Study completedNCT02159365
What this trial is testing

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 84
Not applicableNot Yet RecruitingNCT07015021
What this trial is testing

The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients

Who this might be right for
Multiple MyelomaCarfilzomibDaratumumab+1 more
The First Affiliated Hospital of Soochow University 72
Testing effectiveness (Phase 2)Study completedNCT02963493
What this trial is testing

Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Oncopeptides AB 157
Early research (Phase 1)WithdrawnNCT00547404
What this trial is testing

Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma

Who this might be right for
Multiple Myeloma
Piramal Enterprises Limited 35
Early research (Phase 1)Study completedNCT00079716
What this trial is testing

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

Who this might be right for
Multiple Myeloma
Seagen Inc. 44
Testing effectiveness (Phase 2)Ended earlyNCT04243109
What this trial is testing

Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib

Who this might be right for
Multiple Myeloma
Maimónides Biomedical Research Institute of Córdoba 6
Testing effectiveness (Phase 2)WithdrawnNCT03221634
What this trial is testing

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Who this might be right for
Multiple Myeloma
Merck Sharp & Dohme LLC
Testing effectiveness (Phase 2)WithdrawnNCT01445587
What this trial is testing

GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

Who this might be right for
Cancer
GlaxoSmithKline
Early research (Phase 1)Study completedNCT00858234
What this trial is testing

Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)

Who this might be right for
Multiple Myeloma
Merck Sharp & Dohme LLC 9
Load More Results